Back to search results

MGD024 for Relapsed or Refractory Blood Cancers

This study is testing a new drug called MGD024 for people with certain blood cancers that have come back or haven't responded to standard treatments. MGD024 is designed to help your body's immune cells (T lymphocytes) find and destroy cancer cells. Researchers want to learn about the safety of MGD024, how well your body handles it, and if it has any anti-cancer effects. You could be eligible if you are an adult with specific types of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or classical Hodgkin lymphoma. The main goal is to track any severe side effects and other adverse events during the study.

Study design
This is a Phase 1, open-label study, meaning both you and your doctors will know you are receiving MGD024. It will involve up to 130 participants across multiple centers.
What's involved
You would receive MGD024 in 28-day cycles for up to 12 cycles (about one year), or until your treatment needs to stop.
Compensation
Not stated in the trial record.
Follow-up
Researchers will track side effects and other events throughout your participation, for up to 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05362773

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
MacroGenics
~130 participants
Updated 2026-07-28 on ClinicalTrials.gov
What's tested:MGD024

At a glance

Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of severe side effects in patients receiving MGD024
Measured over First 28 days of the study
+1 more outcome measured

Conditions

Leukemia, Acute Myeloid
Myelodysplastic Syndromes
Classical Hodgkin Lymphoma
Leukemia, B-cell
Leukemia, Hairy Cell
Mastocytosis, Aggressive Systemic
Blastic Plasmacytoid Dendritic Cell Neoplasm
Chronic Myeloid Leukemia

Explore related trials

Acute Myeloid LeukemiaB Acute Lymphoblastic LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmChronic Myeloid Leukemia, BCR-ABL1 PositiveClassic Hodgkin LymphomaHairy Cell LeukemiaHematologic NeoplasmMyelodysplastic SyndromeSystemic Mastocytosis

Where it's being run

7 sites across 7 states
Colorado1
Maryland1
Massachusetts1
Michigan1
Missouri1
North Carolina1
Texas1

Study leadership

  • Frank Perabo, MD, PhD · STUDY_DIRECTOR · MacroGenics

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patients at least 18 years of age, able to provide informed consent and willing to comply with all study procedures.
Participants with
primary or secondary acute myeloid leukemia (AML) except acute promyelocytic leukemia,
primary or secondary myelodysplastic syndrome (MDS) with prognostic score of \>3 and \<20% bone marrow blasts,
classical Hodgkin lymphoma (cHL),
chronic myelogenous leukemia (CML),
b-cell acute lymphocytic leukemia (B-ALL),
hariy cell leukemia (HCL),
advanced systemic mastocytosis (ASM), or
blastic plasmacytoid dendritic cell neoplasm (BPDCM)
Relapsed after or refractory to at least one prior line of therapy and with no available potentially curative treatment option.
Evidence of at least 20% of malignant cells with CD123 expression.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
Life expectancy of at least 12 weeks.
Acceptable laboratory values, and heart function.
Continuing side effects of prior treatment are mild
Women and men of childbearing potential must agree to use highly effective forms of contraception throughout the study through 4 months after the last dose of MGD024.

Exclusion

Prior treatment with an anti-CD123-directed agent (except patients with BPDCN, who are allowed to have received prior tagraxofusp).
Known involvement of central nervous system (CNS) by the disease under investigation.
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient.
Systemic anti-cancer therapy, investigational therapy, corticosteroids or other immune suppressive drugs within 14 days of first dose
Vaccination with any live virus vaccine within 4 weeks prior to first dose. Inactivated annual influenza and SARS-CoV-2 vaccination are allowed.

What this trial measures

  • Number of severe side effects in patients receiving MGD024First 28 days of the study

    Observation of side effects determines the highest safe dose for further study

  • Number and types of adverse events (AEs), including serious adverse events (SAEs), and AEs leading to treatment discontinuation.Throughout study participation, up to 12 months.

    Observation of side effects determines the highest safe dose for further study